Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re³: Infliximab Optimization in RA
NCT00394589Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2006
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in rheumatoid arthritis (RA), sponsored by Merck & Co.. Started Mar 2006; status: terminated.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00394589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394589.